Omapatrilat
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (4S,7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2- sulfanylpropanoyl]amino}-2,3,4,7,8,9,10,10a-octahydropyrido[6,1-b] [1,3]thiazepine-7-carboxylic acid | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 167305-00-2  |
| ATC code | None |
| PubChem | CID 656629 |
| UNII | 36NLI90E7T  |
| ChEMBL | CHEMBL289556 |
| Chemical data | |
| Formula | C19H24N2O4S2 |
| Mol. mass | 408.534 g/mol |
 (what is this?) (verify) |
|
Omapatrilat (INN) is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.
This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.[1]
[edit] Clinical uses
The drug was promoted for possible uses in congestive heart failure.
[edit] References
- ^ Joshi Venugopal. (2003) Pharmacological modulation of the natriuretic peptide system. Expert Opinion on Therapeutic Patents 13:9, 1389
 |
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
